Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07294170 · ClinicalTrials.gov registry record
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
A clinical trial of Myasthenia Gravis and Generalized Myasthenia Gravis, sponsored by argenx.
- Recruiting
- Registry status
- 70
- Enrollment target
- 5
- Study locations
NCT07294170 is a study of Myasthenia Gravis and Generalized Myasthenia Gravis that is actively recruiting participants, run by argenx. The registered enrollment target is 70 participants, below the 189-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (63% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT07294170, a study of Myasthenia Gravis and Generalized Myasthenia Gravis, is actively recruiting participants, sponsored by argenx.
- RECRUITING
- Registry status
- 70 participants
- Enrollment target
- 5
- Study locations
Study Summary
ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life.
Conditions Studied
Interventions
- BIOLOGICAL Efgartigimod IV
- BIOLOGICAL Empasiprubart IV
Study Locations (5)
California
- Profound Research LLC - Carlsbad - Carlsbad
Florida
- Visionary Investigators Network - Miami
Maryland
- Erlanger Health System - Columbia
New York
- Dent Neurologic Institute - Amherst - Amherst
Texas
- National Neuromuscular Research Institute - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2025-12-19 |
| Est. Completion | 2028-03-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07294170
The ClinicalTrials.gov registry entry for NCT07294170 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 189-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (63% lower). The listed sponsor is argenx, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Myasthenia Gravis appearing as the primary indexed condition, and to 2 interventions - of which Efgartigimod IV is the first listed.
NCT07294170 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT07294170 about?
NCT07294170 is a clinical study titled "ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis". ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life.
What is the current status of trial NCT07294170?
This trial is currently recruiting. The enrollment target is 70 participants. The study started on 2025-12-19. Estimated completion is 2028-03-07.
What conditions does trial NCT07294170 study?
This clinical trial studies the following conditions: Myasthenia Gravis, Generalized Myasthenia Gravis, gMG, Generalized Myasthenia Gravis (gMG), MG.
What interventions are being tested in trial NCT07294170?
The interventions under investigation include: Efgartigimod IV (BIOLOGICAL), Empasiprubart IV (BIOLOGICAL).
Who is sponsoring clinical trial NCT07294170?
This trial is sponsored by argenx, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07294170 being conducted?
This trial has 5 study locations across California, Florida, Maryland, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myasthenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
RECRUITING
-
The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis
RECRUITING · NA
-
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
RECRUITING · NA
-
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
Light vs. Moderate Intensity Exercise in Individuals With Myasthenia Gravis
RECRUITING · NA
-
Validation and Scaling of Screening Program for Undiagnosed Myasthenia Gravis-Social Media Campaign Paired With a Self-moderated Assessment
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.